PRDX4

Across TCGA pan-cancer cohorts, PRDX4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRDX4 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRDX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRDX4 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC, COAD, and BLCA are the cancer types where PRDX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.106	0.754	<.001	54	view →
COAD	OS	Median	All	0.121	0.803	<.001	33	view →
BLCA	DFS	Median	IV	1.000	0.336	.022	7	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.100	0.728	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRDX4–HNSC (OS)

Open the HNSC breakdown →